Help
RSS
API
Feed
Maltego
Contact
Domain > biosyngen.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2023-06-17
163.181.66.215
(
ClassC
)
2026-01-16
163.181.60.225
(
ClassC
)
2026-02-02
163.181.246.234
(
ClassC
)
Port 80
HTTP/1.1 200 OKServer: TengineContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveVary: Accept-EncodingSet-Cookie: acw_tca3b5f6a717700523854898585ef52a0c516fe334c82cdc31f49b333ec4;path/;HttpOnly;Max-Age3600Set-Cookie: cdn_sec_tca3b5f6a717700523854898585ef52a0c516fe334c82cdc31f49b333ec4;path/;HttpOnly;Max-Age3600Date: Mon, 02 Feb 2026 17:13:06 GMTVary: Accept-EncodingSet-Cookie: PHPSESSID92sc41h0oskoog3o75bai9dh46; path/Expires: Thu, 19 Nov 1981 08:52:00 GMTCache-Control: no-store, no-cache, must-revalidatePragma: no-cacheStrict-Transport-Security: max-age31536000Via: cache23.l2nu20-8165,0, ens-cache19.us331127,0Timing-Allow-Origin: *EagleId: a3b5f6a717700523854898585e !DOCTYPE HTML>html langzh-CN>head>meta charsetutf-8 />meta http-equivX-UA-Compatible contentIEedge, chrome1 />meta namerenderer contentwebkit />meta nameviewport contentwidthdevice-width, initial-scale1, maximum-scale1, minimum-scale1, user-scalableno />meta nameformat-detection contenttelephoneno />title>Biosyngen/title>meta namekeywords contentBiosyngen>meta namedescription contentBiosyngen>link relstylesheet href/statics/home/css/style.css />script src/statics/home/js/jquery.js>/script>script src/statics/home/js/lib.js>/script>script src/statics/home/js/wow.min.js>/script>link relstylesheet href/statics/home/css/animate.min.css />script>var _hmt _hmt ||;(function() {var hm document.createElement(script);hm.src https://hm.baidu.com/hm.js?d0c396bc919458a0d42a674dc8315284;var s document.getElementsByTagName(script)0;s.parentNode.insertBefore(hm,s);})();/script>/head>body>div classheader>div classwp>div classlogo>a href/>img src/Uploads/image/20231114/e8f2ffa82746d25086d8190f9b7da840.png />/a>/div>div classmenubtn>MENU/div>/div>/div>div classh-snv>div classwp>div classtop>div classlogo>a href/>img src/statics/home/images/logo2.png/>/a>/div>div classclose js-cls>Close/div>/div>ul classul-nav>li class>a href/Technology/ classv1>Technology/a>/li>li class>a href/pipeline/ classv1>Pipeline/a>/li>li class>a href/about/ classv1>About Us/a>/li>li class>a href/news/ classv1>NEWS/a>/li>li class>a href/careers/ classv1>Careers/a>/li>li class>a href/contactus/ classv1>Contact/a>/li>/ul>/div>/div>div classbanner>div classitem>div classpic>img src/Uploads/image/20231130/28ecbaf881b920ba2f779eca001661b7.png />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/about/ target_blank classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231123/4f2b67586b828bd20ac03f603d359a1d.jpg />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a hrefTechnology/ target_self classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231123/ef701ead3bd8437553eff535a53f6b83.jpg />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/pipeline/ target_blank classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231123/5e92a0cf24e3defa3ed8ad59b383f82c.jpg />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/about/ target_blank classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231218/0e98d65a836358b28d1d5b1a923bcd14.png />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/pipeline/ target_self classg-more>span>LEARN MORE /span>/a>/div>/div>/div>/div>div classrow-a1 stylebackground-image: url(/statics/home/images/index/b8.png)>div classg-ani1_1>/div>div classg-ani1_2>/div>div classg-ani1_3>/div>div classg-ani2_1>/div>div classwp>div classm-topa1>div classg-tit wow fadeInUp>Pipelines consisting of 2 proven technologies in CGT (CAR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more /div>div classm-boxa1>div classm-cona1 wow fadeInUp>div classgroup>img src/Uploads/image/20231114/9064abbb85264e31419a7d0a6eca87d0.png />div classtxt>div classtit>No approved cell immunotherapy for solid tumor to date/div>div classdesc>Currently, more than half of clinical trials are focusing on b>blood cancer/b>. However, the larger unmet need and challenge is b>Solid Tumor/b>. /div>/div>/div>div classgroup>img src/Uploads/image/20231114/0bbb67314e04ab0ae11404b1a789a781.png />div classtxt>div classtit>>90% of all cancer patients with solid tumors/div>div classdesc>According to the global cancer data of 2021, b>more than 90% of newly cancer cases worldwide are solid tumor patients/b>, significantly outnumbering patients with blood cancers./div>/div>/div>/div>div classm-cona2 wow>div classarr>img src/statics/home/images/index/a7.png alt />div classinfo>Developing cutting-edge immunotherapies to address unmet needs in oncology/div>/div>/div>div classm-cona1 m-cona3 wow fadeInUp>div classgroup>img src/Uploads/image/20231114/f42c4f9c035c5ebe77975f0880f6e498.png />div classtxt>div classtit>Developing first-in-class (FIC) product against solid tumors/div>div classdesc>Products in the pipeline are b>first-in-class (FIC) against solid tumors/b>, focusing on unmet needs globally, well positioned to fill the gap in the market./div>/div>/div>/div>/div>/div>div classm-cta1 wow fadeInUp>div classg-titbox2>div classg-tit>Pipelines consisting of 2 proven technologies in CGT (CAR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more /div>div classdesc>/div>/div>div classm-boxa2>div classcol-l>ul classul-cta1 TAB_CLICK id.tab1>li classli1 >a hrefjavascript:; classcon>div classinner>img src/Uploads/image/20231114/7774753418585faa7be95eb91fc9da9b.png classbg1 alt />img src/Uploads/image/20231114/eb15f2ac1aef8f28af27cf610ade6710.png classbg2 alt />div classtxt>TCR-T/div>/div>/a>/li>li classli2 on>a hrefjavascript:; classcon>div classinner>img src/Uploads/image/20231114/7774753418585faa7be95eb91fc9da9b.png classbg1 alt />img src/Uploads/image/20231114/eb15f2ac1aef8f28af27cf610ade6710.png classbg2 alt />div classtxt>TIL/div>/div>/a>/li>li classli3 >a hrefjavascript:; classcon>div classinner>img src/Uploads/image/20231114/7774753418585faa7be95eb91fc9da9b.png classbg1 alt />img src/Uploads/image/20231114/eb15f2ac1aef8f28af27cf610ade6710.png classbg2 alt />div classtxt>CAR-T/div>/div>/a>/li>/ul>/div>div classright-box>div classtab1>div classm-concta1>div classtop>TCR-T/div>ul classul-cta2>li>div classcon>div classtit>Biosyngens Differentiation/div>div classdesc>p>· Next generation design enhancing the persistence of T cells in vivo/p>p>· High affinity/avidity/specificity against tumor specific antigen/p> /div>/div>/li>li>div classcon>div classtit>Biosyngens Pipeline/div>div classdesc>/div>/div>/li>/ul>/div>a href/Technology/ target_self classg-more>span>LEARN MORE /span>/a>/div>div classtab1>div classm-concta1>div classtop>TIL/div>ul classul-cta2>li>div classcon>div classtit>Biosyngens Differentiation/div>div classdesc>p>· Able to be cryopreserved to address long distance transportation issue/p>p>· Does not require high dose IL-2 infusion/p> /div>/div>/li>li>div classcon>div classtit>Biosyngens Pipeline/div>div classdesc>p>· BST02: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S./p> /div>/div>/li>/ul>/div>a href/Technology/ target_self classg-more>span>LEARN MORE /span>/a>/div>div classtab1>div classm-concta1>div classtop>CAR-T/div>ul classul-cta2>li>div classcon>div classtit>Biosyngens Differentiation/div>div classdesc>p>· In-human data showing clinical efficacy/p>p>· Unique target/FIC/p>p>· Enhanced safety profile/p> /div>/div>/li>li>div classcon>div classtit>Biosyngens Pipeline/div>div classdesc>p>· BRG01: Ongoing Phase II clinical trials in China/U.S./p>p>· BGT007: Dual CAR-T, IIT in progress/p>p>· ALLO-CEL: In-human by 2024/p> /div>/div>/li>/ul>/div>a href/Technology/ target_self classg-more>span>LEARN MORE /span>/a>/div>/div>/div>/div>div classm-dwa1>div classg-tit wow fadeInUp>Established proprietary technology platforms for R&D translation & br />immunotherapy drug development against solid tumors /div>ul classul-dwa1 wow fadeInUp>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>M-CEL/div>h3 classtit>Automated and intelligent cell manufacturing platform/h3>div classline>/div>/div>div classcover>div classen>M-CEL/div>h3 classtit>Automated and intelligent cell manufacturing platform/h3>div classline>/div>div classdesc>p>· Improved production cycle time of CAR-T/TCR-T product to 10-days./p>p>br>/p>p>· Manufactured in GMP facility in compliance to FDA and CDE requirements./p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>SUPER-T/div>h3 classtit>T cell safety optimization platform/h3>div classline>/div>/div>div classcover>div classen>SUPER-T/div>h3 classtit>T cell safety optimization platform/h3>div classline>/div>div classdesc>p>· Unique T cell signaling tweaking strategy and TME-specific promoter to broaden tumor cell coverage while ensuring safety./p>p>br>/p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>MSE-T/div>h3 classtit>T cell functional enhancement platform /h3>div classline>/div>/div>div classcover>div classen>MSE-T/div>h3 classtit>T cell functional enhancement platform /h3>div classline>/div>div classdesc>p>· Library consisting of hundreds of motifs for T cell functional enhancement./p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>IDENTIFIER/div>h3 classtit>Antigen/Antibody/TCR discovery platform/h3>div classline>/div>/div>div classcover>div classen>IDENTIFIER/div>h3 classtit>Antigen/Antibody/TCR discovery platform/h3>div classline>/div>div classdesc>p>· Large tumor-specific TCR library for multiple high-frequency HLA haplotypes./p>p>br>/p>p>·Fast screening / optimization./p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>/ul>/div>/div>/div>div classrow-a2 stylebackground-image: url(/statics/home/images/index/c8.png)>div classg-ani1_1>/div>div classg-ani1_2>/div>div classg-ani1_3>/div>div classg-ani1_4>/div>div classg-ani1_5>/div>div classg-ani2_1>/div>div classwp>div classm-topa2 wow fadeInUp>div classg-tit>Global strategy to serve patients worldwide with scalable GMP br />production capability and broad clinical network /div>div classm-mapa2>img src/statics/home/images/index/b7.png classbg alt />ul classul-maplist TAB_CLICK>li classli1 on styleleft: 13%; top: 11.6%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>America/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/6651b3f6f80ddc8e8004c31808635b97.png classicon2 alt />img src/Uploads/image/20231201/cb8a6aadeabbc7b646f48da08d5a5907.png classicon3 alt />/div>div classtit>Stanford University School of Medicine/div>div classdesc>p>/p>/div>/div>/li>li classli2 styleleft: 46.83%; top: 13.6%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>France/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/a472d46c66f0b191e5d6f99b20adfa5c.jpg classicon2 alt />img src/Uploads/image/20231201/dea14a20a7ac2868608510b15f18a9bd.jpg classicon3 alt />/div>div classtit>Gustave Roussy Cancer Campus/div>div classdesc>p>/p>/div>/div>/li>li classli3 styleleft: 42.77%; top: 16.5%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>Germany/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/1c810e263e705103f6166e53fb0f774f.jpg classicon2 alt />img src/Uploads/image/20231201/f00c75c85991ae5d52e8d614eb129f79.jpg classicon3 alt />/div>div classtit>Helmholtz Zentrum München-German Research Center/div>div classdesc>p>/p>/div>/div>/li>li classli4 styleright: 18.3%; top: 36.9%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>China/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/1fead37f5fa682d84329d685c1ebdc5e.png classicon2 alt />img src/Uploads/image/20231201/5ed0aaa71b8950458623047dc9789afe.png classicon3 alt />/div>div classtit>Sun Yat-sen University Cancer Center/div>div classdesc>p>/p>/div>/div>/li>li classli5 styleright: 16.7%; bottom: 27.6%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>Singapore/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/07f2f8367809fa3e31725c26398d48e3.jpg classicon2 alt />img src/Uploads/image/20231214/da4c5373cbe50300be151fdf13dbc040.png classicon3 alt />/div>div classtit>The Agency for Science, Technology and Research, Singapore/div>div classdesc>p>/p>/div>/div>/li>li classli6 styleright: 10.12%; bottom: 12%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>Australia/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/0804b8ee991ad47a6442495fba303638.jpg classicon2 alt />img src/Uploads/image/20231201/02dca1c8b740ca72dad4746eb5feea7a.jpg classicon3 alt />/div>div classtit>QIMR Berghofer Medical Research Institute/div>div classdesc>p>/p>/div>/div>/li>/ul>a href/about/ target_blank classg-morem2>LEARN MORE/a>/div>/div>div classm-cta2 wow fadeInUp>div classg-tit>Exclusive Partnership with Public Agencies to pursue breakthrough in development/div>div classm-bancta2 g-arrow g-dot>div classitem>div classinner>div classtop>Abundant clinical resources around the world/div>ul classul-bana2_1>li>div classcon1>img src/statics/home/images/index/c1.png classimg alt />div classtxt>Clinical trials have been initiated at 8 medical centers in China/div>/div>/li>li>div classcon1>img src/statics/home/images/index/c2.png classimg alt />div classtxt>Clinical trials of NCCS are already ongoing in Singapore/div>/div>/li>/ul>div classdw-pic>img src/statics/home/images/index/c3.png alt />/div>/div>/div>div classitem>div classinner>div classtop>Accelerate R&D progress with cooperative of Top scientific research institutions/div>ul classul-bana2_2>li>div classcon2>div classpic>img src/statics/home/images/index/c4.png alt />img src/statics/home/images/index/c5.png alt />/div>div classtxt>p>Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC./p>p>Collaboration targets multiple indications . exclusive collaboration in NPC.br />span>/span>/p>p>13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Governmentspan>/span>/p>/div>/div>/li>/ul>/div>/div>div classitem>div classinner>div classtop>Abundant clinical resources around the world/div>ul classul-bana2_1>li>div classcon1>img src/statics/home/images/index/c1.png classimg alt />div classtxt>Clinical trials have been initiated at 8 medical centers in China/div>/div>/li>li>div classcon1>img src/statics/home/images/index/c2.png classimg alt />div classtxt>Clinical trials of NCCS are already ongoing in Singapore/div>/div>/li>/ul>div classdw-pic>img src/statics/home/images/index/c3.png alt />/div>/div>/div>div classitem>div classinner>div classtop>Accelerate R&D progress with cooperative of Top scientific research institutions/div>ul classul-bana2_2>li>div classcon2>div classpic>img src/statics/home/images/index/c4.png alt />img src/statics/home/images/index/c5.png alt />/div>div classtxt>p>Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC./p>p>Collaboration targets multiple indications . exclusive collaboration in NPC.br />span>/span>/p>p>13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Governmentspan>/span>/p>/div>/div>/li>/ul>/div>/div>/div>/div>div classm-dwa2 wow fadeInUp>div classg-titbox2 g-titbox3>div classg-tit>Dual site strategy/div>div classdesc>p>Dual site strategy with dual R&D and GMP Facilities to address Global needs/p>/div>/div>div classm-bandwa2 g-arrow g-dot>div classitem>div classinner inner1>div classpic>img src/Uploads/image/20231129/1004ce8f73c855bcbe482d62e34fa16b.JPG />/div>div classtxt>Singapore ｜ Largest private GMP Facility in Singapore/div>/div>/div>div classitem>div classinner inner2>div classpic>img src/Uploads/image/20231129/3cbced4b48511cb900e8589f82101f79.JPG />/div>div classtxt>China ｜ The largest GMP Facility in South China /div>/div>/div>/div>/div>/div>/div>div classrow-a3>div classwp>div classg-titbox4 wow fadeInUp>div classtit>Latest Headlines/div>a href/news/ classg-morem2 g-morem3>span>LEARN MORE /span>/a>/div>div classm-a3 wow fadeInUp>div classcol-l>a href/index.php/Classification/4.html classm-a3-l>div classpic>img src/Uploads/image/20231114/4a809c18ea46858efe4892fe62b89071.jpg>/div>div classtxt>div classtit>PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy/div>div classdesc>2023-03-29/div>/div>/a>/div>div classright-box>ul classul-lista4>li>a href/index.php/Classification/44.html classcon>div classpic>img src/Uploads/image/20241113/3205a91537fcaa0af534a4e67cd77da9.jpg>/div>div classtxt>div classtit>SITC 2024 (II): Biosyngen Unveils Next-Generation TIL Development Results – Achieving a Significant Breakthrough in the Treatment of All Types of Liver Cancer/div>div classdesc>2024-11-13/div>/div>/a>/li>li>a href/index.php/Classification/43.html classcon>div classpic>img src/Uploads/image/20241113/399da2c9c45a33fbdab6308ed268ea84.jpg>/div>div classtxt>div classtit>SITC 2024 (I): Historic Breakthrough in Cancer Treatment – Biosyngen’s Fourth-Generation Innovative Therapy Targeting Pan-Digestive Tract Tumors/div>div classdesc>2024-11-13/div>/div>/a>/li>li>a href/index.php/Classification/42.html classcon>div classpic>img src/Uploads/image/20241113/f8c8e182f6f61003d5fd043911f4df2e.JPG>/div>div classtxt>div classtit>Biosyngen Initiates Phase II Trial for BRG01, a Fourth-Generation Tumor Drug Addressing Targeted Toxicity/div>div classdesc>2024-11-11/div>/div>/a>/li>/ul>/div>/div>/div>/div>link relstylesheet href/statics/home/css/slick.css />script typetext/javascript src/statics/home/js/slick.min.js>/script>script>$(document).ready(function() {$(.banner).slick({dots:true,arrows:true,autoplay:true,slidesToShow:1,slidesToScroll:1,autoplaySpeed:6000,pauseOnHover:false,accessibility:false,responsive:{breakpoint:1199,settings:{slidesToShow:1,slidesToScroll:1,dots:true,arrows:false,}}});$(.banner).slick(slickGoTo,0);$(.banner .slick-current).addClass(img_scale);$(.banner).on(beforeChange,function(event,slick,currentSlide,nextSlide) {$(.banner .slick-current).removeClass(img_scale);});$(.banner).on(afterChange,function(event,slick,currentSlide) {$(.banner .slick-current).addClass(img_scale);});$(.m-bancta2).slick({dots:false,arrows:true,autoplay:true,slidesToShow:2,slidesToScroll:2,autoplaySpeed:5000,pauseOnHover:false,accessibility:false,responsive:{breakpoint:1199,settings:{slidesToShow:1,slidesToScroll:1,}},{breakpoint:767,settings:{slidesToShow:1,slidesToScroll:1,dots:true,arrows:false,}}});$(.m-bandwa2).slick({dots:false,arrows:true,autoplay:false,slidesToShow:2,slidesToScroll:2,autoplaySpeed:5000,pauseOnHover:false,accessibility:false,responsive:{breakpoint:1199,settings:{slidesToShow:1,slidesToScroll:1,}},{breakpoint:767,settings:{slidesToShow:1,slidesToScroll:1,dots:true,arrows:false,}}});$(.ul-maplist li).click(function() {clearTimeout(timer);var timer setTimeout(function() {if ($(.ul-maplist li.on).index() $(.ul-maplist li).length - 1) {$(.ul-maplist li).eq(0).trigger(click)} else {$(.ul-maplist li.on).next().trigger(click)}},3000);});$(.ul-maplist li).eq(0).trigger(click)});/script>div classfooter>div classwp fix>div classf-txt f-txt1 pc>a href/ classf-logo>img src/statics/home/images/logo2.png />/a>div classf-copy>p>Copyright © 2023 br/> a hrefhttps://beian.miit.gov.cn/ target_blank>粤ICP备 19085772号/a>/p> /div>/div>div classf-txt f-txt2>div classf-tit>Get in Touch/div>div classf-desc>a href>Taiseng Exchange, 5 Tai Seng Avenue, #08-51/52/53/54, Tower C, Singapore 536671/a>/div>div classf-tels>div classgroup>a hreftel: classtel>/a>a hrefmailto: classemail>/a>/div>/div>/div>div classf-txt f-txt3>div classf-tit>/div>div classf-desc>a href>1-3F., Block B, Building 6, Chuangyan Street, Sino-Singapore Knowledge City, Huangpu District, Guangzhou, P. R. China/a>/div>div classf-tels>div classgroup>a hreftel: classtel>/a>/div>div classf-vx>img src/Uploads/image/20231220/11d5346fa1f54b75ad19e39b1c58d19d.jpg />/div>/div>/div>div classf-txt f-txt4>div classf-tit>Quick Links/div>div classf-links>a href/Technology/ classf1>Technology/a>a href/pipeline/ classf1>Pipeline/a>a href/about/ classf1>About Us/a>a href/news/ classf1>News/a>a href/careers/ classf1>Careers/a>a href/contactus/ classf1>Contact/a>a href/expanded/ classf1>Expanded Access Policy/a>/div>/div>div classf-txt f-txt1 m>a href/ classf-logo>img src/statics/home/images/logo2.png />/a>div classf-copy>p>Copyright © 2023 br/> a hrefhttps://beian.miit.gov.cn/ target_blank>粤ICP备 19085772号/a>/p> /div>/div>/div>/div>script>$(document).ready(function() {if (!/msie 6|7|8|9/i.test(navigator.userAgent)) {var wow new WOW({boxClass:wow,animateClass:animated,offset:0,mobile:false,live:true,});wow.init();}});/script>script>$(document).ready(function() {$(.sel-nav).hover(function() {$(this).children(.ul-sel1).stop().slideToggle();});});/script>/body>/html>
Port 443
HTTP/1.1 200 OKServer: TengineContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveVary: Accept-EncodingSet-Cookie: acw_tca3b5f69817700523870891824e84bf6ee02820ea75d879f6d5aba71c4c;path/;HttpOnly;Max-Age3600Set-Cookie: cdn_sec_tca3b5f69817700523870891824e84bf6ee02820ea75d879f6d5aba71c4c;path/;HttpOnly;Max-Age3600Date: Mon, 02 Feb 2026 17:13:07 GMTVary: Accept-EncodingSet-Cookie: PHPSESSIDo1cfl52p4d26mp72j3jju9qpd7; path/Expires: Thu, 19 Nov 1981 08:52:00 GMTCache-Control: no-store, no-cache, must-revalidatePragma: no-cacheStrict-Transport-Security: max-age31536000Via: ens-cache42.l2eo166-17167,0, ens-cache4.us33395,0Timing-Allow-Origin: *EagleId: a3b5f69817700523870891824e !DOCTYPE HTML>html langzh-CN>head>meta charsetutf-8 />meta http-equivX-UA-Compatible contentIEedge, chrome1 />meta namerenderer contentwebkit />meta nameviewport contentwidthdevice-width, initial-scale1, maximum-scale1, minimum-scale1, user-scalableno />meta nameformat-detection contenttelephoneno />title>Biosyngen/title>meta namekeywords contentBiosyngen>meta namedescription contentBiosyngen>link relstylesheet href/statics/home/css/style.css />script src/statics/home/js/jquery.js>/script>script src/statics/home/js/lib.js>/script>script src/statics/home/js/wow.min.js>/script>link relstylesheet href/statics/home/css/animate.min.css />script>var _hmt _hmt ||;(function() {var hm document.createElement(script);hm.src https://hm.baidu.com/hm.js?d0c396bc919458a0d42a674dc8315284;var s document.getElementsByTagName(script)0;s.parentNode.insertBefore(hm,s);})();/script>/head>body>div classheader>div classwp>div classlogo>a href/>img src/Uploads/image/20231114/e8f2ffa82746d25086d8190f9b7da840.png />/a>/div>div classmenubtn>MENU/div>/div>/div>div classh-snv>div classwp>div classtop>div classlogo>a href/>img src/statics/home/images/logo2.png/>/a>/div>div classclose js-cls>Close/div>/div>ul classul-nav>li class>a href/Technology/ classv1>Technology/a>/li>li class>a href/pipeline/ classv1>Pipeline/a>/li>li class>a href/about/ classv1>About Us/a>/li>li class>a href/news/ classv1>NEWS/a>/li>li class>a href/careers/ classv1>Careers/a>/li>li class>a href/contactus/ classv1>Contact/a>/li>/ul>/div>/div>div classbanner>div classitem>div classpic>img src/Uploads/image/20231130/28ecbaf881b920ba2f779eca001661b7.png />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/about/ target_blank classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231123/4f2b67586b828bd20ac03f603d359a1d.jpg />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a hrefTechnology/ target_self classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231123/ef701ead3bd8437553eff535a53f6b83.jpg />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/pipeline/ target_blank classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231123/5e92a0cf24e3defa3ed8ad59b383f82c.jpg />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/about/ target_blank classg-more>span>LEARN MORE /span>/a>/div>/div>/div>div classitem>div classpic>img src/Uploads/image/20231218/0e98d65a836358b28d1d5b1a923bcd14.png />div classtxt>div classtit>span classspan1>span classspan5>G/span>/span>iving/span> span classspan2>span classspan5>P/span>/span>atients span classspan3>/span>the span classspan3>span classspan5>B/span>/span>est span classspan4>span classspan5>C/span>/span>hance span classspan-6>/span>to span classspan-5>span classspan5>S/span>/span>urvive/div>div classdesc>Biosyngen is a Global Leader in Cell Therapy. br>We design cutting-edge immunotherapies aiming to provide patients the best treatment option./div>a href/pipeline/ target_self classg-more>span>LEARN MORE /span>/a>/div>/div>/div>/div>div classrow-a1 stylebackground-image: url(/statics/home/images/index/b8.png)>div classg-ani1_1>/div>div classg-ani1_2>/div>div classg-ani1_3>/div>div classg-ani2_1>/div>div classwp>div classm-topa1>div classg-tit wow fadeInUp>Pipelines consisting of 2 proven technologies in CGT (CAR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more /div>div classm-boxa1>div classm-cona1 wow fadeInUp>div classgroup>img src/Uploads/image/20231114/9064abbb85264e31419a7d0a6eca87d0.png />div classtxt>div classtit>No approved cell immunotherapy for solid tumor to date/div>div classdesc>Currently, more than half of clinical trials are focusing on b>blood cancer/b>. However, the larger unmet need and challenge is b>Solid Tumor/b>. /div>/div>/div>div classgroup>img src/Uploads/image/20231114/0bbb67314e04ab0ae11404b1a789a781.png />div classtxt>div classtit>>90% of all cancer patients with solid tumors/div>div classdesc>According to the global cancer data of 2021, b>more than 90% of newly cancer cases worldwide are solid tumor patients/b>, significantly outnumbering patients with blood cancers./div>/div>/div>/div>div classm-cona2 wow>div classarr>img src/statics/home/images/index/a7.png alt />div classinfo>Developing cutting-edge immunotherapies to address unmet needs in oncology/div>/div>/div>div classm-cona1 m-cona3 wow fadeInUp>div classgroup>img src/Uploads/image/20231114/f42c4f9c035c5ebe77975f0880f6e498.png />div classtxt>div classtit>Developing first-in-class (FIC) product against solid tumors/div>div classdesc>Products in the pipeline are b>first-in-class (FIC) against solid tumors/b>, focusing on unmet needs globally, well positioned to fill the gap in the market./div>/div>/div>/div>/div>/div>div classm-cta1 wow fadeInUp>div classg-titbox2>div classg-tit>Pipelines consisting of 2 proven technologies in CGT (CAR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more /div>div classdesc>/div>/div>div classm-boxa2>div classcol-l>ul classul-cta1 TAB_CLICK id.tab1>li classli1 >a hrefjavascript:; classcon>div classinner>img src/Uploads/image/20231114/7774753418585faa7be95eb91fc9da9b.png classbg1 alt />img src/Uploads/image/20231114/eb15f2ac1aef8f28af27cf610ade6710.png classbg2 alt />div classtxt>TCR-T/div>/div>/a>/li>li classli2 on>a hrefjavascript:; classcon>div classinner>img src/Uploads/image/20231114/7774753418585faa7be95eb91fc9da9b.png classbg1 alt />img src/Uploads/image/20231114/eb15f2ac1aef8f28af27cf610ade6710.png classbg2 alt />div classtxt>TIL/div>/div>/a>/li>li classli3 >a hrefjavascript:; classcon>div classinner>img src/Uploads/image/20231114/7774753418585faa7be95eb91fc9da9b.png classbg1 alt />img src/Uploads/image/20231114/eb15f2ac1aef8f28af27cf610ade6710.png classbg2 alt />div classtxt>CAR-T/div>/div>/a>/li>/ul>/div>div classright-box>div classtab1>div classm-concta1>div classtop>TCR-T/div>ul classul-cta2>li>div classcon>div classtit>Biosyngens Differentiation/div>div classdesc>p>· Next generation design enhancing the persistence of T cells in vivo/p>p>· High affinity/avidity/specificity against tumor specific antigen/p> /div>/div>/li>li>div classcon>div classtit>Biosyngens Pipeline/div>div classdesc>/div>/div>/li>/ul>/div>a href/Technology/ target_self classg-more>span>LEARN MORE /span>/a>/div>div classtab1>div classm-concta1>div classtop>TIL/div>ul classul-cta2>li>div classcon>div classtit>Biosyngens Differentiation/div>div classdesc>p>· Able to be cryopreserved to address long distance transportation issue/p>p>· Does not require high dose IL-2 infusion/p> /div>/div>/li>li>div classcon>div classtit>Biosyngens Pipeline/div>div classdesc>p>· BST02: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S./p> /div>/div>/li>/ul>/div>a href/Technology/ target_self classg-more>span>LEARN MORE /span>/a>/div>div classtab1>div classm-concta1>div classtop>CAR-T/div>ul classul-cta2>li>div classcon>div classtit>Biosyngens Differentiation/div>div classdesc>p>· In-human data showing clinical efficacy/p>p>· Unique target/FIC/p>p>· Enhanced safety profile/p> /div>/div>/li>li>div classcon>div classtit>Biosyngens Pipeline/div>div classdesc>p>· BRG01: Ongoing Phase II clinical trials in China/U.S./p>p>· BGT007: Dual CAR-T, IIT in progress/p>p>· ALLO-CEL: In-human by 2024/p> /div>/div>/li>/ul>/div>a href/Technology/ target_self classg-more>span>LEARN MORE /span>/a>/div>/div>/div>/div>div classm-dwa1>div classg-tit wow fadeInUp>Established proprietary technology platforms for R&D translation & br />immunotherapy drug development against solid tumors /div>ul classul-dwa1 wow fadeInUp>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>M-CEL/div>h3 classtit>Automated and intelligent cell manufacturing platform/h3>div classline>/div>/div>div classcover>div classen>M-CEL/div>h3 classtit>Automated and intelligent cell manufacturing platform/h3>div classline>/div>div classdesc>p>· Improved production cycle time of CAR-T/TCR-T product to 10-days./p>p>br>/p>p>· Manufactured in GMP facility in compliance to FDA and CDE requirements./p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>SUPER-T/div>h3 classtit>T cell safety optimization platform/h3>div classline>/div>/div>div classcover>div classen>SUPER-T/div>h3 classtit>T cell safety optimization platform/h3>div classline>/div>div classdesc>p>· Unique T cell signaling tweaking strategy and TME-specific promoter to broaden tumor cell coverage while ensuring safety./p>p>br>/p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>MSE-T/div>h3 classtit>T cell functional enhancement platform /h3>div classline>/div>/div>div classcover>div classen>MSE-T/div>h3 classtit>T cell functional enhancement platform /h3>div classline>/div>div classdesc>p>· Library consisting of hundreds of motifs for T cell functional enhancement./p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>li>div classcon>div classdefault>div classicon>img src/Uploads/image/20231114/c052b1d471f2ff7627aa2e65a140cab3.png />/div>div classen>IDENTIFIER/div>h3 classtit>Antigen/Antibody/TCR discovery platform/h3>div classline>/div>/div>div classcover>div classen>IDENTIFIER/div>h3 classtit>Antigen/Antibody/TCR discovery platform/h3>div classline>/div>div classdesc>p>· Large tumor-specific TCR library for multiple high-frequency HLA haplotypes./p>p>br>/p>p>·Fast screening / optimization./p> /div>div classmore>a href target_blank>LEARN MORE /a>/div>/div>/div>/li>/ul>/div>/div>/div>div classrow-a2 stylebackground-image: url(/statics/home/images/index/c8.png)>div classg-ani1_1>/div>div classg-ani1_2>/div>div classg-ani1_3>/div>div classg-ani1_4>/div>div classg-ani1_5>/div>div classg-ani2_1>/div>div classwp>div classm-topa2 wow fadeInUp>div classg-tit>Global strategy to serve patients worldwide with scalable GMP br />production capability and broad clinical network /div>div classm-mapa2>img src/statics/home/images/index/b7.png classbg alt />ul classul-maplist TAB_CLICK>li classli1 on styleleft: 13%; top: 11.6%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>America/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/6651b3f6f80ddc8e8004c31808635b97.png classicon2 alt />img src/Uploads/image/20231201/cb8a6aadeabbc7b646f48da08d5a5907.png classicon3 alt />/div>div classtit>Stanford University School of Medicine/div>div classdesc>p>/p>/div>/div>/li>li classli2 styleleft: 46.83%; top: 13.6%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>France/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/a472d46c66f0b191e5d6f99b20adfa5c.jpg classicon2 alt />img src/Uploads/image/20231201/dea14a20a7ac2868608510b15f18a9bd.jpg classicon3 alt />/div>div classtit>Gustave Roussy Cancer Campus/div>div classdesc>p>/p>/div>/div>/li>li classli3 styleleft: 42.77%; top: 16.5%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>Germany/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/1c810e263e705103f6166e53fb0f774f.jpg classicon2 alt />img src/Uploads/image/20231201/f00c75c85991ae5d52e8d614eb129f79.jpg classicon3 alt />/div>div classtit>Helmholtz Zentrum München-German Research Center/div>div classdesc>p>/p>/div>/div>/li>li classli4 styleright: 18.3%; top: 36.9%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>China/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/1fead37f5fa682d84329d685c1ebdc5e.png classicon2 alt />img src/Uploads/image/20231201/5ed0aaa71b8950458623047dc9789afe.png classicon3 alt />/div>div classtit>Sun Yat-sen University Cancer Center/div>div classdesc>p>/p>/div>/div>/li>li classli5 styleright: 16.7%; bottom: 27.6%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>Singapore/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/07f2f8367809fa3e31725c26398d48e3.jpg classicon2 alt />img src/Uploads/image/20231214/da4c5373cbe50300be151fdf13dbc040.png classicon3 alt />/div>div classtit>The Agency for Science, Technology and Research, Singapore/div>div classdesc>p>/p>/div>/div>/li>li classli6 styleright: 10.12%; bottom: 12%>div classcon>div classbox>img src/statics/home/images/index/b6.png classicon alt />div classtxt>Australia/div>/div>/div>div classinfobox>div classiconbox>img src/Uploads/image/20231201/0804b8ee991ad47a6442495fba303638.jpg classicon2 alt />img src/Uploads/image/20231201/02dca1c8b740ca72dad4746eb5feea7a.jpg classicon3 alt />/div>div classtit>QIMR Berghofer Medical Research Institute/div>div classdesc>p>/p>/div>/div>/li>/ul>a href/about/ target_blank classg-morem2>LEARN MORE/a>/div>/div>div classm-cta2 wow fadeInUp>div classg-tit>Exclusive Partnership with Public Agencies to pursue breakthrough in development/div>div classm-bancta2 g-arrow g-dot>div classitem>div classinner>div classtop>Abundant clinical resources around the world/div>ul classul-bana2_1>li>div classcon1>img src/statics/home/images/index/c1.png classimg alt />div classtxt>Clinical trials have been initiated at 8 medical centers in China/div>/div>/li>li>div classcon1>img src/statics/home/images/index/c2.png classimg alt />div classtxt>Clinical trials of NCCS are already ongoing in Singapore/div>/div>/li>/ul>div classdw-pic>img src/statics/home/images/index/c3.png alt />/div>/div>/div>div classitem>div classinner>div classtop>Accelerate R&D progress with cooperative of Top scientific research institutions/div>ul classul-bana2_2>li>div classcon2>div classpic>img src/statics/home/images/index/c4.png alt />img src/statics/home/images/index/c5.png alt />/div>div classtxt>p>Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC./p>p>Collaboration targets multiple indications . exclusive collaboration in NPC.br />span>/span>/p>p>13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Governmentspan>/span>/p>/div>/div>/li>/ul>/div>/div>div classitem>div classinner>div classtop>Abundant clinical resources around the world/div>ul classul-bana2_1>li>div classcon1>img src/statics/home/images/index/c1.png classimg alt />div classtxt>Clinical trials have been initiated at 8 medical centers in China/div>/div>/li>li>div classcon1>img src/statics/home/images/index/c2.png classimg alt />div classtxt>Clinical trials of NCCS are already ongoing in Singapore/div>/div>/li>/ul>div classdw-pic>img src/statics/home/images/index/c3.png alt />/div>/div>/div>div classitem>div classinner>div classtop>Accelerate R&D progress with cooperative of Top scientific research institutions/div>ul classul-bana2_2>li>div classcon2>div classpic>img src/statics/home/images/index/c4.png alt />img src/statics/home/images/index/c5.png alt />/div>div classtxt>p>Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC./p>p>Collaboration targets multiple indications . exclusive collaboration in NPC.br />span>/span>/p>p>13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Governmentspan>/span>/p>/div>/div>/li>/ul>/div>/div>/div>/div>div classm-dwa2 wow fadeInUp>div classg-titbox2 g-titbox3>div classg-tit>Dual site strategy/div>div classdesc>p>Dual site strategy with dual R&D and GMP Facilities to address Global needs/p>/div>/div>div classm-bandwa2 g-arrow g-dot>div classitem>div classinner inner1>div classpic>img src/Uploads/image/20231129/1004ce8f73c855bcbe482d62e34fa16b.JPG />/div>div classtxt>Singapore ｜ Largest private GMP Facility in Singapore/div>/div>/div>div classitem>div classinner inner2>div classpic>img src/Uploads/image/20231129/3cbced4b48511cb900e8589f82101f79.JPG />/div>div classtxt>China ｜ The largest GMP Facility in South China /div>/div>/div>/div>/div>/div>/div>div classrow-a3>div classwp>div classg-titbox4 wow fadeInUp>div classtit>Latest Headlines/div>a href/news/ classg-morem2 g-morem3>span>LEARN MORE /span>/a>/div>div classm-a3 wow fadeInUp>div classcol-l>a href/index.php/Classification/4.html classm-a3-l>div classpic>img src/Uploads/image/20231114/4a809c18ea46858efe4892fe62b89071.jpg>/div>div classtxt>div classtit>PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy/div>div classdesc>2023-03-29/div>/div>/a>/div>div classright-box>ul classul-lista4>li>a href/index.php/Classification/44.html classcon>div classpic>img src/Uploads/image/20241113/3205a91537fcaa0af534a4e67cd77da9.jpg>/div>div classtxt>div classtit>SITC 2024 (II): Biosyngen Unveils Next-Generation TIL Development Results – Achieving a Significant Breakthrough in the Treatment of All Types of Liver Cancer/div>div classdesc>2024-11-13/div>/div>/a>/li>li>a href/index.php/Classification/43.html classcon>div classpic>img src/Uploads/image/20241113/399da2c9c45a33fbdab6308ed268ea84.jpg>/div>div classtxt>div classtit>SITC 2024 (I): Historic Breakthrough in Cancer Treatment – Biosyngen’s Fourth-Generation Innovative Therapy Targeting Pan-Digestive Tract Tumors/div>div classdesc>2024-11-13/div>/div>/a>/li>li>a href/index.php/Classification/42.html classcon>div classpic>img src/Uploads/image/20241113/f8c8e182f6f61003d5fd043911f4df2e.JPG>/div>div classtxt>div classtit>Biosyngen Initiates Phase II Trial for BRG01, a Fourth-Generation Tumor Drug Addressing Targeted Toxicity/div>div classdesc>2024-11-11/div>/div>/a>/li>/ul>/div>/div>/div>/div>link relstylesheet href/statics/home/css/slick.css />script typetext/javascript src/statics/home/js/slick.min.js>/script>script>$(document).ready(function() {$(.banner).slick({dots:true,arrows:true,autoplay:true,slidesToShow:1,slidesToScroll:1,autoplaySpeed:6000,pauseOnHover:false,accessibility:false,responsive:{breakpoint:1199,settings:{slidesToShow:1,slidesToScroll:1,dots:true,arrows:false,}}});$(.banner).slick(slickGoTo,0);$(.banner .slick-current).addClass(img_scale);$(.banner).on(beforeChange,function(event,slick,currentSlide,nextSlide) {$(.banner .slick-current).removeClass(img_scale);});$(.banner).on(afterChange,function(event,slick,currentSlide) {$(.banner .slick-current).addClass(img_scale);});$(.m-bancta2).slick({dots:false,arrows:true,autoplay:true,slidesToShow:2,slidesToScroll:2,autoplaySpeed:5000,pauseOnHover:false,accessibility:false,responsive:{breakpoint:1199,settings:{slidesToShow:1,slidesToScroll:1,}},{breakpoint:767,settings:{slidesToShow:1,slidesToScroll:1,dots:true,arrows:false,}}});$(.m-bandwa2).slick({dots:false,arrows:true,autoplay:false,slidesToShow:2,slidesToScroll:2,autoplaySpeed:5000,pauseOnHover:false,accessibility:false,responsive:{breakpoint:1199,settings:{slidesToShow:1,slidesToScroll:1,}},{breakpoint:767,settings:{slidesToShow:1,slidesToScroll:1,dots:true,arrows:false,}}});$(.ul-maplist li).click(function() {clearTimeout(timer);var timer setTimeout(function() {if ($(.ul-maplist li.on).index() $(.ul-maplist li).length - 1) {$(.ul-maplist li).eq(0).trigger(click)} else {$(.ul-maplist li.on).next().trigger(click)}},3000);});$(.ul-maplist li).eq(0).trigger(click)});/script>div classfooter>div classwp fix>div classf-txt f-txt1 pc>a href/ classf-logo>img src/statics/home/images/logo2.png />/a>div classf-copy>p>Copyright © 2023 br/> a hrefhttps://beian.miit.gov.cn/ target_blank>粤ICP备 19085772号/a>/p> /div>/div>div classf-txt f-txt2>div classf-tit>Get in Touch/div>div classf-desc>a href>Taiseng Exchange, 5 Tai Seng Avenue, #08-51/52/53/54, Tower C, Singapore 536671/a>/div>div classf-tels>div classgroup>a hreftel: classtel>/a>a hrefmailto: classemail>/a>/div>/div>/div>div classf-txt f-txt3>div classf-tit>/div>div classf-desc>a href>1-3F., Block B, Building 6, Chuangyan Street, Sino-Singapore Knowledge City, Huangpu District, Guangzhou, P. R. China/a>/div>div classf-tels>div classgroup>a hreftel: classtel>/a>/div>div classf-vx>img src/Uploads/image/20231220/11d5346fa1f54b75ad19e39b1c58d19d.jpg />/div>/div>/div>div classf-txt f-txt4>div classf-tit>Quick Links/div>div classf-links>a href/Technology/ classf1>Technology/a>a href/pipeline/ classf1>Pipeline/a>a href/about/ classf1>About Us/a>a href/news/ classf1>News/a>a href/careers/ classf1>Careers/a>a href/contactus/ classf1>Contact/a>a href/expanded/ classf1>Expanded Access Policy/a>/div>/div>div classf-txt f-txt1 m>a href/ classf-logo>img src/statics/home/images/logo2.png />/a>div classf-copy>p>Copyright © 2023 br/> a hrefhttps://beian.miit.gov.cn/ target_blank>粤ICP备 19085772号/a>/p> /div>/div>/div>/div>script>$(document).ready(function() {if (!/msie 6|7|8|9/i.test(navigator.userAgent)) {var wow new WOW({boxClass:wow,animateClass:animated,offset:0,mobile:false,live:true,});wow.init();}});/script>script>$(document).ready(function() {$(.sel-nav).hover(function() {$(this).children(.ul-sel1).stop().slideToggle();});});/script>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]